Hematology Times
|
|
LeukemiasTosedostat passes phase 1/2 test in AML
Bone marrow aspirate
showing AML Researchers have confirmed the antileukemic activity of once daily oral doses of the aminopeptidase inhibitor tosedostat as montherapy in elderly and/or relapsing patients with acute myeloid leukemia (AML), myelodysplasia, or multiple myeloma. Seven of 51 AML patients achieved a complete marrow response and 3 achieved complete remission with the maximum-acceptable dose of 130 mg. Investigators reported the results August 23 online ahead of print in the Journal of Clinical Oncology. ... [Read Article] Cryopreservation may be unsafe in leukemia
 A common way of preserving fertility during cancer treatment may cause relapse in acute lymphocytic leukemia (ALL) patients. A recent study published in the journal Blood found that some mice that received grafts of ovarian tissue samples from women with ALL developed tumors. Mice that received ovarian tissue grafts from women with chronic myelogenous leukemia (CML), however, did not develop tumors. ... [Read Article] Series of assays could identify imatinib resistance
CML cells
Researchers in Japan have developed a series of assays that may help predict which chronic myeloid leukemia (CML) patients will resist imatinib therapies. Currently, between 2% and 10% of patients become resistant to the CML standard of care, depending on the definition. New treatments being developed and tested for CML, such as dasatinib and nilotinib, are believed to overcome imatinib resistance. However, it is still a challenge to determine who will become resistant. ... [Read Article] UCB transplant is viable option for adult acute leukemia
Cord blood extraction
A recent study published online in The Lancet Oncology is the first analysis to show similar leukemia-free survival in adult acute leukemia patients who receive unrelated donor umbilical cord blood (UCB) transplants mismatched for 1 or 2 human leukocyte antigens (HLAs) and patients who receive allele-matched bone marrow or peripheral blood progenitor cell (PBPC) transplants. The use of UCB could provide a viable option for patients who urgently need a transplant or cannot find a PBPC or bone marrow donor. ... [Read Article] New agent active in relapsed/refractory malignancies
Jennifer Brown, MD, PhD
A PI3Kd inhibitor demonstrates considerable activity in certain relapsed or refractory hematologic malignancies. Jennifer Brown, MD, PhD, of Dana-Farber Cancer Institute, and her fellow researchers administered CAL-101 to 106 patients with various relapsed or refractory diseases. Forty-five percent of patients had NHL, 33% had CLL, 11% had acute myeloid leukemia, and 11% of patients had multiple myeloma. “Fifty-five percent had disease refractory to their most recent prior therapy,” Dr Brown said. “And the patients had a median of 5 prior therapies, which emphasizes what a difficult patient population this was.” ... [Read Article] |
|